Canadian Biosimilar Resources

Explaining biosimilars

Information describing what biosimilars are, how they are approved in Canada, and what diseases they treat, can be found in the following resources:

- Health Canada Biosimilars Fact Sheet
- ✤ Canadian Biosimilars Forum
- Canadian Digestive Health Foundation (CDHF): Biosimilar Library
- Arthritis Society
- Arthritis Consumer Experts (ACE): Biosim Exchange

Canadian Biosimilar Transition Policies:

Multiple public and private insurance providers have implemented biosimilar transition policies in Canada. Policy details and results from some of these policies are publicly available:

- British Columbia Biosimilars Initiative Policy and Data
- British Columbia Biosimilars Initiative Health Services Utilization
- Alberta Biosimilars Initiative Policy
- Albert Biosimilars Initiative Data
- New Brunswick Biosimilars Initiative Policy
- Pacific Blue Cross Biosimilar Transition Policy
- Green Shield Biosimilar Transition Policy

Financial considerations of biosimilars on private drug plans:

Canadian private insurance providers have reported on the financial impact of their biosimilar policies:

- Green Shield Biosimilar Transition Policy Saved \$8,500 per Plan Member Annually
- Pacific Blue Cross Saved \$22 Million for Plan Sponsors and Members with their Biosimilar Transition Policy
- Equitable Life: Risk of Not Coordinating with Alberta Public Transition Policy

Patient Tools for Biosimilar Transition

Multiple Canadian resources exist to help patients and physicians discuss transitioning to a biosimilar:

- Patient Journey when Transitioning to a Biosimilar Animated Video
- ✤ ACE Biosimilars Transition Infographic
- ACE Biosimilars Education Video: Transitioning to a Biosimilar
- ACE Biosimilars Education Video: Helping Patients Manage the Transition
- CDHF: Transition Pathway Brochure for IBD Patients
- CDHF Video: Transitioning to a Biosimilar